Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

China flag China · Delayed Price · Currency is CNY
23.35
-0.46 (-1.93%)
Mar 2, 2026, 3:04 PM CST
9.93%
Market Cap 24.19B
Revenue (ttm) 6.02B
Net Income (ttm) 1.23B
Shares Out 1.02B
EPS (ttm) 1.21
PE Ratio 19.67
Forward PE 19.20
Dividend 0.36 (1.51%)
Ex-Dividend Date May 14, 2025
Volume 6,924,520
Average Volume 8,438,645
Open 23.72
Previous Close 23.81
Day's Range 23.24 - 23.83
52-Week Range 20.36 - 29.30
Beta -0.28
RSI 49.15
Earnings Date Apr 18, 2026

About SHE:002262

Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine fumarate, injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, duloxetine hydrochloride enteric dissolving capsules, olan... [Read more]

Sector Healthcare
Founded 1978
Employees 5,923
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002262
Full Company Profile

Financial Performance

In 2024, SHE:002262's revenue was 5.70 billion, an increase of 13.01% compared to the previous year's 5.04 billion. Earnings were 1.14 billion, an increase of 10.28%.

Financial Statements

News

Luye Pharma Grants Nhwa Rights To Commercialize Three LAI Antipsychotics In Chinese Mainland

(RTTNews) - The board of Luye Pharma Group Ltd. (2186.HK) announced that certain subsidiaries of the Group have entered into an agreement with Jiangsu Nhwa Hexin Pharmaceutical Marketing Co., a subsid...

2 months ago - Nasdaq